Phase 2Completed
NAD+ Precursor Supplementation in Friedreich's Ataxia
A Phase 2a Study of NAD+ Precursor Supplementation in Friedreich's Ataxia
- Sponsor
- Metro International Biotech, LLC (Industry)
- Enrolment
- 7 enrolled
- Conditions
- Friedreich Ataxia
- Interventions
- MIB-626
- Ages
- adults
- Registry
- NCT04817111
From the registry
The primary objective is to test the safety and tolerability of short-term therapy with a nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%. A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle bioenergetics.
Primary outcomes
- Percentage of Individuals With Treatment-emergent Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 5.0.